Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update
February 18, 2022 18:12 ET
|
Ocugen
MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
February 18, 2022 17:25 ET
|
Ocugen
MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and...
Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options
February 15, 2022 07:25 ET
|
Ocugen
73% of Americans would like to see additional COVID-19 vaccines be available that are developed from a more traditional method40% of parents whose children under age 18 are not yet vaccinated say they...
Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada
January 27, 2022 09:25 ET
|
Ocugen
Dormant Vaccine Manufacturing site currently owned by an affiliate of Liminal BioSciences intended to bring new capabilities to Ocugen’s medicine portfolio of Canadian and U.S. companiesCOVAXIN™...
Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety
January 24, 2022 07:12 ET
|
Ocugen
MALVERN, Pa., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 21, 2022 18:12 ET
|
Ocugen
MALVERN, Pa., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2
January 12, 2022 06:43 ET
|
Ocugen
Booster dose of candidate vaccine, COVAXIN™ (BBV152), generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) using a live virus neutralization assay100%...
COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety
January 08, 2022 18:27 ET
|
Ocugen
Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, Beta, Delta and Delta Plus variants) in neutralizing titers compared...
Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference
January 06, 2022 18:03 ET
|
Ocugen
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS
December 30, 2021 09:59 ET
|
Ocugen
COVAXIN™ whole virus inactivated vaccine generated broad antibody response comparable to those seen in a large phase 3 trial in adults 18+Adverse events were primarily mild, and no serious adverse...